Skip to main content
. 2018 Mar 12;21(2):325–334. doi: 10.1007/s10456-018-9598-5

Table 1.

Baseline demographics and bleeding events of patients treated with sunitinib and bevacizumab

Sunitinib Bevacizumab
N 17 8
Male/female 10/7 5/3
Mean age in years (range) 59 (42–73) 57 (47–70)
RCC 17 0
NSCLC 0 8
Mean platelet count pretreatment * 109 (range) 359 (49–930) 212 (106–324)
Bleeding event 8
Grade one 6
Grade three 1
Grade four 1

Renal cell cancer (RCC), non-small cell lung carcinoma (NSCLC)

N is the number of patients